ProPhet Bio
Rehovot, Israel· Est.
AI‑powered platform that rapidly identifies small‑molecule binders for undruggable proteins, delivering hit‑finding at unprecedented speed and scale.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
AI‑powered platform that rapidly identifies small‑molecule binders for undruggable proteins, delivering hit‑finding at unprecedented speed and scale.
Technology Platform
AI-driven interaction‑space mapping that embeds proteins and small molecules into a shared latent space, enabling ultra‑fast, structure‑agnostic screening of billions of compounds.
Opportunities
Rapid, scalable hit‑finding for undruggable targets could attract large pharma partnerships and open new therapeutic spaces.
Risk Factors
Unproven predictive accuracy at scale and lack of disclosed funding may hinder partnership formation and commercial traction.
Competitive Landscape
Competes with AI‑driven discovery platforms such as Insilico Medicine and Atomwise; differentiation lies in its lightweight, sequence‑only modeling approach.